{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:21Z","timestamp":1791924441986,"version":"4.3.4"},"reference-count":311,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02443-1","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:21:54Z","timestamp":1762874514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-4578","authenticated-orcid":false,"given":"Somayeh","family":"Yazdanparast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-3095","authenticated-orcid":false,"given":"Mehdi","family":"Bakhtiyaridovvombaygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Davoodi-Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-541X","authenticated-orcid":false,"given":"Gelayol","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6618-4641","authenticated-orcid":false,"given":"Fatemeh","family":"Monjezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5260-0564","authenticated-orcid":false,"given":"Pegah","family":"Kiyamehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-585X","authenticated-orcid":false,"given":"Ahmad","family":"Gharehbaghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-4994","authenticated-orcid":false,"given":"Saeid","family":"Abroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-3975","authenticated-orcid":false,"given":"Nahid","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"3","key":"2443_CR1","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2020.9054","volume":"12","author":"N Bolli","year":"2020","unstructured":"Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep. 2020;12(3):9054.","journal-title":"Hematol Rep"},{"key":"2443_CR2","doi-asserted-by":"crossref","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, Manier S, Mohty M. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45.","DOI":"10.1038\/s41572-024-00529-7"},{"issue":"5","key":"2443_CR3","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/curroncol30050334","volume":"30","author":"BE Monteith","year":"2023","unstructured":"Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023;30(5):4382\u2013401.","journal-title":"Curr Oncol"},{"key":"2443_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2017.11.016","volume":"121","author":"G Cook","year":"2018","unstructured":"Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P. A question of class: treatment options for patients with relapsed and\/or refractory multiple myeloma. Crit Rev Oncol Hematol. 2018;121:74\u201389.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2443_CR5","doi-asserted-by":"publisher","unstructured":"Legarda MA, Cejalvo MJ, de la Rubia J. Recent advances in the treatment of patients with multiple myeloma. Cancers (Basel). 2020;12(12):3576. https:\/\/doi.org\/10.3390\/cancers12123576.","DOI":"10.3390\/cancers12123576"},{"key":"2443_CR6","doi-asserted-by":"publisher","unstructured":"D\u2019Agostino M, Bertamini L, Oliva S, Boccadoro M, Gay F. Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies. Cancers (Basel). 2019;11(12):2015. https:\/\/doi.org\/10.3390\/cancers11122015.","DOI":"10.3390\/cancers11122015"},{"issue":"1","key":"2443_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","volume":"13","author":"K Bisht","year":"2024","unstructured":"Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A, et al. Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities. Exp Hematol Oncol. 2024;13(1):114.","journal-title":"Exp Hematol Oncol"},{"key":"2443_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.816499","volume":"12","author":"O Venglar","year":"2021","unstructured":"Venglar O, Bago JR, Motais B, Hajek R, Jelinek T. Natural killer cells in the malignant niche of multiple myeloma. Front Immunol. 2021;12:816499.","journal-title":"Front Immunol"},{"issue":"6","key":"2443_CR9","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","volume":"17","author":"R Elahi","year":"2021","unstructured":"Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev Rep. 2021;17(6):2081\u2013106.","journal-title":"Stem Cell Rev Rep"},{"key":"2443_CR10","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1182\/blood-2023-191338","volume":"142","author":"D Gadhiya","year":"2023","unstructured":"Gadhiya D, Amin V, Kamani Y, Mahesh G, Kotak K, Ratheesh R, et al. Global burden and trends of multiple myeloma in high-income North America countries between 1990\u20132019, with projections of deaths to 2040: a benchmarking analysis for the Global Burden of Disease Study 2019. Blood. 2023;142:2004.","journal-title":"Blood"},{"issue":"8","key":"2443_CR11","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","volume":"111","author":"H Ludwig","year":"2008","unstructured":"Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111(8):4039\u201347.","journal-title":"Blood"},{"key":"2443_CR12","first-page":"99","volume":"2024","author":"A Luis","year":"2024","unstructured":"Luis A. Multiple myeloma: a comprehensive review of clinical feature and management. Glob J Res Analysis. 2024;2024:99\u2013101.","journal-title":"Glob J Res Analysis"},{"key":"2443_CR13","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceed. 2003: Elsevier.","DOI":"10.4065\/78.1.21"},{"issue":"11","key":"2443_CR14","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1002\/cncr.20652","volume":"101","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ III. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101(11):2667\u201374.","journal-title":"Cancer"},{"issue":"1","key":"2443_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar K, Chauhan D, Anderson K. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10\u201324.","journal-title":"Leukemia"},{"issue":"11","key":"2443_CR16","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, et al. Activin a promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010;107(11):5124\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2443_CR17","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/jbmr.2387","volume":"29","author":"MT Drake","year":"2014","unstructured":"Drake MT. Unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance? J Bone Miner Res. 2014;29(12):2529\u201333.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2443_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","volume":"150","author":"JR Berenson","year":"2010","unstructured":"Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150(1):28\u201338.","journal-title":"Br J Haematol"},{"issue":"3","key":"2443_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1586\/17474086.2015.1029449","volume":"8","author":"SV Glavey","year":"2015","unstructured":"Glavey SV, Ghobrial IM. American Society of Hematology annual meeting 2014: highlights in multiple myeloma. Expert Rev Hematol. 2015;8(3):273\u20135.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2443_CR20","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2443_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.20517\/cdr.2022.23","volume":"5","author":"JJ Ignatz-Hoover","year":"2022","unstructured":"Ignatz-Hoover JJ, Driscoll JJ. Therapeutics to harness the immune microenvironment in multiple myeloma. Cancer Drug Resist. 2022;5(3):647\u201361.","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"2443_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3249.BCDSYMP24-P06","volume":"5","author":"S Shivaram","year":"2024","unstructured":"Shivaram S, Tang H, Yan H, Tian S, Qin G, Anderson E, et al. Abstract P06: characterization of the immune tumor microenvironment in a diverse cohort of patients with multiple myeloma. Blood Cancer Discov. 2024;5(2):P06-P.","journal-title":"Blood Cancer Discov"},{"key":"2443_CR23","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1182\/blood-2023-187814","volume":"142","author":"S Vicenzi","year":"2023","unstructured":"Vicenzi S, Tran T, Avsharian L, Hartman J, Rapp A, Crews L. Tuning the innate immune multiple myeloma microenvironment by modulating IRF4. Blood. 2023;142:6604.","journal-title":"Blood"},{"issue":"7","key":"2443_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3712","volume":"26","author":"X Wang","year":"2024","unstructured":"Wang X, Feng Y, Wang F, Lin Z, Huang J, Li Q, et al. Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition. J Gene Med. 2024;26(7):e3712.","journal-title":"J Gene Med"},{"key":"2443_CR25","doi-asserted-by":"publisher","unstructured":"Diaz-Tejedor A, Lorenzo-Mohamed M, Puig N, Garcia-Sanz R, Mateos MV, Garayoa M, et al. Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers (Basel). 2021;13(6):1353. https:\/\/doi.org\/10.3390\/cancers13061353.","DOI":"10.3390\/cancers13061353"},{"issue":"1","key":"2443_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14(1):194.","journal-title":"Blood Cancer J"},{"issue":"5","key":"2443_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2217\/rme.14.35","volume":"9","author":"E Buzhor","year":"2014","unstructured":"Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y, et al. Cell-based therapy approaches: the hope for incurable diseases. Regen Med. 2014;9(5):649\u201372.","journal-title":"Regen Med"},{"issue":"Supplement 1","key":"2443_CR28","doi-asserted-by":"publisher","first-page":"7110","DOI":"10.1182\/blood-2023-173576","volume":"142","author":"Y Yang","year":"2023","unstructured":"Yang Y, Binder AF, Bi X, Filicko-O\u2019Hara J, O\u2019Hara W, Flomenberg N, et al. Outcome of multiple myeloma patients undergoing allogeneic stem cell transplant with post-transplant cyclophosphamide - a single center experience. Blood. 2023;142(Supplement 1):7110.","journal-title":"Blood"},{"issue":"1","key":"2443_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00900-z","volume":"13","author":"WM Schmidt","year":"2023","unstructured":"Schmidt WM, Perera ND, Buadi FK, Hayman SR, Kumar SK, Dispenzieri A, et al. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. Blood Cancer J. 2023;13(1):126.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2443_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-018-0346-9","volume":"120","author":"K Kriegsmann","year":"2019","unstructured":"Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, et al. Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer. 2019;120(1):38\u201344.","journal-title":"Br J Cancer"},{"issue":"6","key":"2443_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27892","volume":"10","author":"MC Vo","year":"2024","unstructured":"Vo MC, Jung SH, Nguyen VT, Tran VD, Ruzimurodov N, Kim SK, et al. Exploring cellular immunotherapy platforms in multiple myeloma. Heliyon. 2024;10(6):e27892.","journal-title":"Heliyon"},{"issue":"8","key":"2443_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","volume":"37","author":"Y Abe","year":"2009","unstructured":"Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, et al. Clinical and immunological evaluation of zoledronate-activated V\u03b39\u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009;37(8):956\u201368.","journal-title":"Exp Hematol"},{"issue":"24","key":"2443_CR33","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.7150\/jca.31752","volume":"10","author":"M Li","year":"2019","unstructured":"Li M, Xia B, Wang Y, You MJ, Zhang Y. Potential therapeutic roles of exosomes in multiple myeloma: a systematic review. J Cancer. 2019;10(24):6154.","journal-title":"J Cancer"},{"key":"2443_CR34","doi-asserted-by":"publisher","unstructured":"Greil C, Engelhardt M, Finke J, Wasch R. Allogeneic stem cell transplantation in multiple myeloma. Cancers (Basel). 2021;14(1):55. https:\/\/doi.org\/10.3390\/cancers14010055.","DOI":"10.3390\/cancers14010055"},{"issue":"5","key":"2443_CR35","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-022-03322-1","volume":"72","author":"JL Thangaraj","year":"2023","unstructured":"Thangaraj JL, Jung SH, Vo MC, Chu TH, Phan MT, Lee KH, et al. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model. Cancer Immunol Immunother. 2023;72(5):1233\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2443_CR36","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","volume":"97","author":"TK Garg","year":"2012","unstructured":"Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97(9):1348\u201356.","journal-title":"Haematologica"},{"issue":"4","key":"2443_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jcyt.2020.09.009","volume":"23","author":"A Tschan-Plessl","year":"2021","unstructured":"Tschan-Plessl A, Kalberer CP, Wieboldt R, Stern M, Siegler U, Wodnar-Filipowicz A, et al. Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma. Cytotherapy. 2021;23(4):329\u201338.","journal-title":"Cytotherapy"},{"issue":"6","key":"2443_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267475","volume":"17","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ng YY, Du Z, Li Z, Chen C, Xiao L, et al. V\u03b39v\u03b42 T cells expressing a bcma\u2014specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. PLoS One. 2022;17(6):e0267475.","journal-title":"PLoS One"},{"issue":"4","key":"2443_CR39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"10","key":"2443_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37(10):1779\u201388.","journal-title":"Curr Med Res Opin"},{"issue":"10297","key":"2443_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"key":"2443_CR42","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.","journal-title":"Front Immunol"},{"key":"2443_CR43","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124.","journal-title":"Front Immunol"},{"issue":"8","key":"2443_CR44","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood-2012-07-442558","volume":"121","author":"SC Chiang","year":"2013","unstructured":"Chiang SC, Theorell J, Entesarian M, Meeths M, Mastafa M, Al-Herz W, et al. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood. 2013;121(8):1345\u201356.","journal-title":"Blood"},{"issue":"10","key":"2443_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri3044","volume":"11","author":"JC Sun","year":"2011","unstructured":"Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8\u207a T cells. Nat Rev Immunol. 2011;11(10):645\u201357.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2443_CR46","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000382019","volume":"7","author":"MM Berrien-Elliott","year":"2015","unstructured":"Berrien-Elliott MM, Wagner JA, Fehniger TA. Human cytokine-induced memory-like natural killer cells. J Innate Immun. 2015;7(6):563\u201371.","journal-title":"J Innate Immun"},{"key":"2443_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00347","volume":"3","author":"P Carrega","year":"2012","unstructured":"Carrega P, Ferlazzo G. Natural killer cell distribution and trafficking in human tissues. Front Immunol. 2012;3:347.","journal-title":"Front Immunol"},{"issue":"8","key":"2443_CR48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/bmt.2016.88","volume":"51","author":"J Dmytrus","year":"2016","unstructured":"Dmytrus J, Matthes-Martin S, Pichler H, Worel N, Geyeregger R, Frank N, et al. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant. 2016;51(8):1093\u2013100.","journal-title":"Bone Marrow Transplant"},{"key":"2443_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1600-065X.2006.00451.x","volume":"214","author":"AG Freud","year":"2006","unstructured":"Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56\u201372.","journal-title":"Immunol Rev"},{"issue":"5","key":"2443_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.","journal-title":"Nat Immunol"},{"issue":"11","key":"2443_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633\u201340.","journal-title":"Trends Immunol"},{"issue":"5","key":"2443_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495\u2013502.","journal-title":"Nat Immunol"},{"issue":"5","key":"2443_CR53","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","volume":"47","author":"AG Freud","year":"2017","unstructured":"Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820\u201333.","journal-title":"Immunity"},{"issue":"4","key":"2443_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.immuni.2015.09.013","volume":"43","author":"TE O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Immunity. 2015;43(4):634\u201345.","journal-title":"Immunity"},{"issue":"4","key":"2443_CR55","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/JLB.1MA0720-654RR","volume":"108","author":"PA Kobyzeva","year":"2020","unstructured":"Kobyzeva PA, Streltsova MA, Erokhina SA, Kanevskiy LM, Telford WG, Sapozhnikov AM, et al. CD56(dim) CD57(-) NKG2C(+) NK cells retaining proliferative potential are possible precursors of CD57(+) NKG2C(+) memory-like NK cells. J Leukoc Biol. 2020;108(4):1379\u201395.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2443_CR56","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1073\/pnas.1012356108","volume":"108","author":"A De Maria","year":"2011","unstructured":"De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A. 2011;108(2):728\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2443_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","volume":"128","author":"NJ Topham","year":"2009","unstructured":"Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009;128(1):7\u201315.","journal-title":"Immunology"},{"issue":"5209","key":"2443_CR58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.7716543","volume":"268","author":"M Colonna","year":"1995","unstructured":"Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science. 1995;268(5209):405\u20138.","journal-title":"Science"},{"issue":"3","key":"2443_CR59","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2567.2010.03398.x","volume":"132","author":"KS Campbell","year":"2011","unstructured":"Campbell KS, Purdy AK. Structure\/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(3):315\u201325.","journal-title":"Immunology"},{"issue":"1","key":"2443_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18(1):29.","journal-title":"Mol Cancer"},{"issue":"2","key":"2443_CR61","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4049\/jimmunol.182.2.829","volume":"182","author":"A S\u00e1ez-Border\u00edas","year":"2009","unstructured":"S\u00e1ez-Border\u00edas A, Romo N, Magri G, Gum\u00e1 M, Angulo A, L\u00f3pez-Botet M. IL-12-dependent inducible expression of the CD94\/NKG2A inhibitory receptor regulates CD94\/NKG2C+ NK cell function. J Immunol. 2009;182(2):829\u201336.","journal-title":"J Immunol"},{"issue":"6669","key":"2443_CR62","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O\u2019Callaghan CA, S\u00f6derstr\u00f6m K, D\u2019Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature. 1998;391(6669):795\u20139.","journal-title":"Nature"},{"key":"2443_CR63","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","volume":"9","author":"D Schmiedel","year":"2018","unstructured":"Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol. 2018;9:2040.","journal-title":"Front Immunol"},{"issue":"3","key":"2443_CR64","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4049\/jimmunol.169.3.1395","volume":"169","author":"MA Holmes","year":"2002","unstructured":"Holmes MA, Li P, Petersdorf EW, Strong RK. Structural studies of allelic diversity of the MHC class I homolog MIC-B, a stress-inducible ligand for the activating immunoreceptor NKG2D. J Immunol. 2002;169(3):1395\u2013400.","journal-title":"J Immunol"},{"issue":"2","key":"2443_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","volume":"14","author":"D Cosman","year":"2001","unstructured":"Cosman D, M\u00fcllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULbps, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123\u201333.","journal-title":"Immunity"},{"key":"2443_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/178698","volume":"2015","author":"C Fionda","year":"2015","unstructured":"Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 ligands: molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma. Biomed Res Int. 2015;2015:178698.","journal-title":"Biomed Res Int"},{"issue":"17","key":"2443_CR67","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood-2013-03-489054","volume":"122","author":"F Baychelier","year":"2013","unstructured":"Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debr\u00e9 P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood. 2013;122(17):2935\u201342.","journal-title":"Blood"},{"key":"2443_CR68","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","volume":"10","author":"AD Barrow","year":"2019","unstructured":"Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol. 2019;10:909.","journal-title":"Front Immunol"},{"key":"2443_CR69","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2741\/2735","volume":"13","author":"M Claus","year":"2008","unstructured":"Claus M, Meinke S, Bhat R, Watzl C. Regulation of NK cell activity by 2B4, NTB-A and CRACC. Front Biosci. 2008;13:956\u201365.","journal-title":"Front Biosci"},{"key":"2443_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02809","volume":"9","author":"L Agresta","year":"2018","unstructured":"Agresta L, Hoebe KHN, Janssen EM. The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front Immunol. 2018;9:2809.","journal-title":"Front Immunol"},{"key":"2443_CR71","doi-asserted-by":"publisher","unstructured":"Zambello R, Baril\u00e0 G, Manni S, Piazza F, Semenzato G. NK cells and CD38: implication for (immuno)therapy in plasma cell dyscrasias. Cells. 2020;9(3):768. https:\/\/doi.org\/10.3390\/cells9030768.","DOI":"10.3390\/cells9030768"},{"key":"2443_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6437057","volume":"2020","author":"Y Chen","year":"2020","unstructured":"Chen Y, Lu D, Churov A, Fu R. Research progress on NK cell receptors and their signaling pathways. Mediators Inflamm. 2020;2020:6437057.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"2443_CR73","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/eji.1830270230","volume":"27","author":"M Carretero","year":"1997","unstructured":"Carretero M, Cantoni C, Bell\u00f3n T, Bottino C, Biassoni R, Rodr\u00edguez A, et al. The CD94 and NKG2-A c-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol. 1997;27(2):563\u20137.","journal-title":"Eur J Immunol"},{"issue":"4","key":"2443_CR74","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.molimm.2004.07.031","volume":"42","author":"F Borrego","year":"2005","unstructured":"Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of the human natural killer cell CD94\/NKG2A inhibitory receptor. Mol Immunol. 2005;42(4):485\u20138.","journal-title":"Mol Immunol"},{"key":"2443_CR75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-065X.1997.tb00945.x","volume":"155","author":"M Colonna","year":"1997","unstructured":"Colonna M. Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Immunol Rev. 1997;155:127\u201333.","journal-title":"Immunol Rev"},{"key":"2443_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fimmu.2012.00258","volume":"3","author":"S Rajagopalan","year":"2012","unstructured":"Rajagopalan S, Long EO. KIR2DL4 (CD158d): an activation receptor for HLA-G. Front Immunol. 2012;3:258.","journal-title":"Front Immunol"},{"key":"2443_CR77","first-page":"23","volume":"298","author":"AWT MacFarlane","year":"2006","unstructured":"MacFarlane AWT, Campbell KS. Signal transduction in natural killer cells. Curr Top Microbiol Immunol. 2006;298:23\u201357.","journal-title":"Curr Top Microbiol Immunol."},{"issue":"4","key":"2443_CR78","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nri3799","volume":"15","author":"L Martinet","year":"2015","unstructured":"Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15(4):243\u201354.","journal-title":"Nat Rev Immunol"},{"key":"2443_CR79","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1600-065X.2008.00660.x","volume":"224","author":"EO Long","year":"2008","unstructured":"Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008;224:70\u201384.","journal-title":"Immunol Rev"},{"issue":"5","key":"2443_CR80","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"4","key":"2443_CR81","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"SR Jaiswal","year":"2017","unstructured":"Jaiswal SR, Zaman S, Nedunchezhian M, Chakrabarti A, Bhakuni P, Ahmed M, et al. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. Cytotherapy. 2017;19(4):531\u201342.","journal-title":"Cytotherapy"},{"issue":"16","key":"2443_CR82","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu LC, Lopez-Verg\u00e8s S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119(16):3734\u201343.","journal-title":"Blood"},{"issue":"10","key":"2443_CR83","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00262-010-0893-2","volume":"59","author":"F Garrido","year":"2010","unstructured":"Garrido F, Algarra I, Garc\u00eda-Lora AM. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible \u201chard\u201d lesions. Cancer Immunol Immunother. 2010;59(10):1601\u20136.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2443_CR84","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","volume":"105","author":"E Carbone","year":"2005","unstructured":"Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251\u20138.","journal-title":"Blood"},{"issue":"3","key":"2443_CR85","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461\u20139.","journal-title":"Blood"},{"issue":"22","key":"2443_CR86","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047\u201356.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2443_CR87","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1096\/fj.08-111005","volume":"23","author":"ME Guicciardi","year":"2009","unstructured":"Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23(6):1625\u201337.","journal-title":"FASEB J"},{"issue":"8","key":"2443_CR88","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835\u201347.","journal-title":"Nat Immunol"},{"key":"2443_CR89","doi-asserted-by":"publisher","unstructured":"Ghasemi M, Abbasi L, Ghanbari Naeini L, Kokabian P, Nameh Goshay Fard N, Givtaj N. Dendritic cells and natural killer cells: the road to a successful oncolytic virotherapy. Front Immunol. 2023;13:950079. https:\/\/doi.org\/10.3389\/fimmu.2022.950079.","DOI":"10.3389\/fimmu.2022.950079"},{"issue":"1","key":"2443_CR90","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13287-021-02251-7","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Rahman HS, Thangavelu L, Dorofeev A, Bayas-Morej\u00f3n F, Shirafkan N, et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther. 2021;12(1):200.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"2443_CR91","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38(4):454\u201372.","journal-title":"Cancer Cell"},{"key":"2443_CR92","doi-asserted-by":"publisher","unstructured":"Ho C, Wallace PK, Attwood K, Parker S, Mohammadpour H, Herr M, et al. Immune cell differences between patients in different stages of monoclonal plasma cell disorders. J Clin Oncol. 2022;40(16_suppl):8065.https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8065.","DOI":"10.1200\/JCO.2022.40.16_suppl.8065"},{"issue":"6","key":"2443_CR93","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17474086.2019.1617128","volume":"12","author":"AM Khan","year":"2019","unstructured":"Khan AM, Devarakonda S, Bumma N, Chaudhry M, Benson DM Jr. Potential of NK cells in multiple myeloma therapy. Expert Rev Hematol. 2019;12(6):425\u201335.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2443_CR94","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bbmt.2018.11.015","volume":"25","author":"M Bhutani","year":"2019","unstructured":"Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, et al. Peripheral immunotype correlates with minimal residual disease status and is modulated by immunomodulatory drugs in multiple myeloma. Biol Blood Marrow Transplant. 2019;25(3):459\u201365.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2443_CR95","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","volume":"75","author":"A Ponzetta","year":"2015","unstructured":"Ponzetta A, Benigni G, Antonangeli F, Sciume G, Sanseviero E, Zingoni A, et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res. 2015;75(22):4766\u201377.","journal-title":"Cancer Res"},{"key":"2443_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0751-5","volume":"7","author":"V Bonanni","year":"2019","unstructured":"Bonanni V, Antonangeli F, Santoni A, Bernardini G. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells. J Immunother Cancer. 2019;7:1\u201316.","journal-title":"J Immunother Cancer"},{"issue":"18","key":"2443_CR97","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","volume":"67","author":"YM El-Sherbiny","year":"2007","unstructured":"El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67(18):8444\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"2443_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020226","volume":"13","author":"T Pazina","year":"2021","unstructured":"Pazina T, MacFarlane AW IV, Bernabei L, Dulaimi E, Kotcher R, Yam C, et al. Alterations of NK cell phenotype in the disease course of multiple myeloma. Cancers. 2021;13(2):226.","journal-title":"Cancers"},{"issue":"12","key":"2443_CR99","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1182\/blood.2023023529","volume":"14","author":"E Blanquart","year":"2024","unstructured":"Blanquart E, Ekren R, Rigaud B, Joubert MV, Baylot V, Daunes H, et al. NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma. Blood. 2024;14(12):1271\u201383.","journal-title":"Blood"},{"issue":"1","key":"2443_CR100","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1264562","volume":"6","author":"C Sun","year":"2017","unstructured":"Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology. 2017;6(1):e1264562.","journal-title":"Oncoimmunology"},{"issue":"7","key":"2443_CR101","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/abbs\/gmu041","volume":"46","author":"M Gao","year":"2014","unstructured":"Gao M, Gao L, Yang G, Tao Y, Hou J, Xu H, et al. Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim Biophys Sin. 2014;46(7):597\u2013604.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"4","key":"2443_CR102","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093721","volume":"5","author":"MV Mart\u00ednez-S\u00e1nchez","year":"2016","unstructured":"Mart\u00ednez-S\u00e1nchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, et al. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2016;5(4):e1093721.","journal-title":"Oncoimmunology"},{"issue":"11","key":"2443_CR103","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jclinpath-2016-203614","volume":"69","author":"G Konjevi\u0107","year":"2016","unstructured":"Konjevi\u0107 G, Vuleti\u0107 A, Martinovi\u0107 KM, Colovi\u0107 N, \u010colovi\u0107 M, Juri\u0161i\u0107 V. Decreased CD161 activating and increased CD158a inhibitory receptor expression on NK cells underlies impaired NK cell cytotoxicity in patients with multiple myeloma. J Clin Pathol. 2016;69(11):1009\u201316.","journal-title":"J Clin Pathol"},{"issue":"2","key":"2443_CR104","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108\u201319.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2443_CR105","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","volume":"30","author":"E Malek","year":"2016","unstructured":"Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 2016;30(5):341\u20138.","journal-title":"Blood Rev"},{"issue":"1","key":"2443_CR106","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240\u20139.","journal-title":"J Immunol"},{"issue":"15","key":"2443_CR107","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","volume":"20","author":"Y Mao","year":"2014","unstructured":"Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20(15):4096\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2443_CR108","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","volume":"24","author":"A Stiff","year":"2018","unstructured":"Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor-mediated natural killer cell function. Clin Cancer Res. 2018;24(8):1891\u2013904.","journal-title":"Clin Cancer Res"},{"key":"2443_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11:1371.","journal-title":"Front Immunol"},{"issue":"13","key":"2443_CR110","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1182\/blood-2006-03-006700","volume":"108","author":"M Della Chiesa","year":"2006","unstructured":"Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates nk-cell function. Blood. 2006;108(13):4118\u201325.","journal-title":"Blood"},{"key":"2443_CR111","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.molimm.2018.09.011","volume":"103","author":"J Zhang","year":"2018","unstructured":"Zhang J, Han X, Hu X, Jin F, Gao Z, Yin L, et al. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D\/NKG2DLs via promoting miR-18a. Mol Immunol. 2018;103:144\u201355.","journal-title":"Mol Immunol"},{"issue":"5","key":"2443_CR112","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.4049\/jimmunol.1501881","volume":"196","author":"CC Goh","year":"2016","unstructured":"Goh CC, Roggerson KM, Lee HC, Golden-Mason L, Rosen HR, Hahn YS. Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN-gamma production by altering cellular metabolism via Arginase-1. J Immunol. 2016;196(5):2283\u201392.","journal-title":"J Immunol"},{"key":"2443_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00771","volume":"10","author":"A Bruno","year":"2019","unstructured":"Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol. 2019;10:771.","journal-title":"Front Immunol"},{"issue":"2","key":"2443_CR114","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105\u201315.","journal-title":"Immunology"},{"issue":"8","key":"2443_CR115","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/15384047.2018.1450116","volume":"19","author":"F Li","year":"2018","unstructured":"Li F, Zhao Y, Wei L, Li S, Liu J. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018;19(8):695\u2013705.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2443_CR116","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1038\/s41598-024-62298-3","volume":"14","author":"D Zhang","year":"2024","unstructured":"Zhang D, Zhan D, Zhang R, Sun Y, Duan C, Yang J, et al. Treg-derived TGF-beta1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma. Sci Rep. 2024;14(1):11593.","journal-title":"Sci Rep"},{"issue":"8","key":"2443_CR117","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.20051511","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202(8):1075\u201385.","journal-title":"J Exp Med"},{"issue":"3","key":"2443_CR118","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.4049\/jimmunol.176.3.1582","volume":"176","author":"MJ Smyth","year":"2006","unstructured":"Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006;176(3):1582\u20137.","journal-title":"J Immunol"},{"issue":"3","key":"2443_CR119","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/icb.2010.100","volume":"89","author":"AE Serrano","year":"2011","unstructured":"Serrano AE, Menares-Castillo E, Garrido-Tapia M, Ribeiro CH, Hern\u00e1ndez CJ, Mendoza-Naranjo A, et al. Interleukin 10 decreases MICA expression on melanoma cell surface. Immunol Cell Biol. 2011;89(3):447\u201357.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"2443_CR120","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3390\/curroncol30070455","volume":"30","author":"E Cencini","year":"2023","unstructured":"Cencini E, Sicuranza A, Ciofini S, Fabbri A, Bocchia M, Gozzetti A. Tumor-associated macrophages in multiple myeloma: key role in disease biology and potential therapeutic implications. Curr Oncol. 2023;30(7):6111\u201333.","journal-title":"Curr Oncol"},{"issue":"1","key":"2443_CR121","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1189\/jlb.3A1215-552R","volume":"101","author":"T Krneta","year":"2017","unstructured":"Krneta T, Gillgrass A, Poznanski S, Chew M, Lee AJ, Kolb M, et al. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. J Leukoc Biol. 2017;101(1):285\u201395.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"2443_CR122","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4049\/jimmunol.1700737","volume":"200","author":"SY Nunez","year":"2018","unstructured":"Nunez SY, Ziblat A, Secchiari F, Torres NI, Sierra JM, Raffo Iraolagoitia XL, et al. Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-beta and Engagement of CD85j. J Immunol. 2018;200(3):1008\u201315.","journal-title":"J Immunol"},{"key":"2443_CR123","doi-asserted-by":"publisher","unstructured":"Botana IF, Moussay E, Paggetti J. Natural killer cells and bone marrow mesenchymal stem cells: a dangerous liaison in multiple myeloma. Clin Transl Discov. 2022;2:e116. https:\/\/doi.org\/10.1002\/ctd2.116.","DOI":"10.1002\/ctd2.116"},{"issue":"Supplement 1","key":"2443_CR124","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1182\/blood-2021-152389","volume":"138","author":"R Fu","year":"2021","unstructured":"Fu R, Deng L, Liu Z, Liu H, Shao Z. Study of bone marrow mesenchymal stem cells regulating NK cells function through Tigit\/ CD226 in patients with multiple myeloma. Blood. 2021;138(Supplement 1):2685.","journal-title":"Blood"},{"key":"2443_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1193978","volume":"13","author":"Z Ding","year":"2023","unstructured":"Ding Z, Shi R, Hu W, Tian L, Sun R, Wu Y, et al. Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets. Front Oncol. 2023;13:1193978.","journal-title":"Front Oncol"},{"issue":"1","key":"2443_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01737-7","volume":"22","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Cheng L, Liu L, Li X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol Cancer. 2023;22(1):34.","journal-title":"Mol Cancer"},{"key":"2443_CR127","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","volume":"75","author":"MR Reagan","year":"2015","unstructured":"Reagan MR, Liaw L, Rosen CJ, Ghobrial IM. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone. 2015;75:161\u20139.","journal-title":"Bone"},{"issue":"3","key":"2443_CR128","doi-asserted-by":"publisher","first-page":"e09167","DOI":"10.1016\/j.heliyon.2022.e09167","volume":"8","author":"C Uhl","year":"2022","unstructured":"Uhl C, Nyirenda T, Siegel DS, Lee WY, Zilberberg J. Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production. Heliyon. 2022;8(3):e09167.","journal-title":"Heliyon"},{"issue":"13","key":"2443_CR129","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286\u201394.","journal-title":"Blood"},{"issue":"44","key":"2443_CR130","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143\u201353.","journal-title":"Oncogene"},{"key":"2443_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.739976","volume":"12","author":"W Jiang","year":"2022","unstructured":"Jiang W, Li F, Jiang Y, Li S, Liu X, Xu Y, et al. Tim-3 blockade elicits potent anti-multiple myeloma immunity of natural killer cells. Front Oncol. 2022;12:739976.","journal-title":"Front Oncol"},{"issue":"17","key":"2443_CR132","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1182\/bloodadvances.2022007905","volume":"6","author":"F Seymour","year":"2022","unstructured":"Seymour F, Cavenagh JD, Mathews J, Gribben JG. NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma. Blood Adv. 2022;6(17):5152\u20139.","journal-title":"Blood Adv"},{"issue":"10","key":"2443_CR133","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/bloodadvances.2019000953","volume":"4","author":"C Barberi","year":"2020","unstructured":"Barberi C, De Pasquale C, Allegra A, Sidoti Migliore G, Oliveri D, Loiacono F, et al. Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules. Blood Adv. 2020;4(10):2297\u2013307.","journal-title":"Blood Adv"},{"issue":"11","key":"2443_CR134","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","volume":"6","author":"J Daly","year":"2022","unstructured":"Daly J, Sarkar S, Natoni A, Stark JC, Riley NM, Bertozzi CR, et al. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell\u2013mediated tumor responses. Blood Adv. 2022;6(11):3352\u201366.","journal-title":"Blood Adv"},{"issue":"4","key":"2443_CR135","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0711293105","volume":"105","author":"M Jinushi","year":"2008","unstructured":"Jinushi M, Vanneman M, Munshi NC, Tai Y-T, Prabhala RH, Ritz J, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105(4):1285\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2443_CR136","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00262-009-0807-3","volume":"59","author":"M von Lilienfeld-Toal","year":"2010","unstructured":"von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother. 2010;59:829\u201339.","journal-title":"Cancer Immunol Immunother"},{"key":"2443_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1059715","volume":"10","author":"PS Rana","year":"2022","unstructured":"Rana PS, Soler DC, Kort J, Driscoll JJ. Targeting TGF-beta signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction. Front Cell Dev Biol. 2022;10:1059715.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2443_CR138","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1007\/s00277-024-05843-4","volume":"103","author":"HY Xue","year":"2024","unstructured":"Xue HY, Wei F. TGF-beta: an active participant in the immune and metabolic microenvironment of multiple myeloma\u202f: TGF-beta in the microenvironment of multiple myeloma. Ann Hematol. 2024;103(11):4351\u201362.","journal-title":"Ann Hematol"},{"issue":"2","key":"2443_CR139","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.intimp.2013.06.003","volume":"17","author":"B Yang","year":"2013","unstructured":"Yang B, Liu H, Shi W, Wang Z, Sun S, Zhang G, et al. Blocking transforming growth factor-\u03b2 signaling pathway augments antitumor effect of adoptive NK-92 cell therapy. Int Immunopharmacol. 2013;17(2):198\u2013204.","journal-title":"Int Immunopharmacol"},{"key":"2443_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-247","volume":"10","author":"G Bonanno","year":"2012","unstructured":"Bonanno G, Mariotti A, Procoli A, Folgiero V, Natale D, De Rosa L, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Transl Med. 2012;10:247.","journal-title":"J Transl Med"},{"issue":"7","key":"2443_CR141","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4014\/jmb.2304.04023","volume":"33","author":"HH Lee","year":"2023","unstructured":"Lee HH, Kang H, Cho H. Role of interleukin(IL)-6 in NK activity to hypoxic-induced highly invasive hepatocellular carcinoma(HCC) cells. J Microbiol Biotechnol. 2023;33(7):864\u201374.","journal-title":"J Microbiol Biotechnol"},{"issue":"2","key":"2443_CR142","first-page":"28","volume":"13","author":"ZY Lu","year":"1995","unstructured":"Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells. 1995;13(2):28\u201334.","journal-title":"Stem Cells"},{"key":"2443_CR143","doi-asserted-by":"publisher","unstructured":"Kim S, Chung H, Kwak JE, Kim YR, Park CH, Kim Y, et al. Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma. J Immunother Cancer. 2024;12(1):e007886. https:\/\/doi.org\/10.1136\/jitc-2023-007886.","DOI":"10.1136\/jitc-2023-007886"},{"issue":"9","key":"2443_CR144","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3109\/10428194.2012.676175","volume":"53","author":"J Godfrey","year":"2012","unstructured":"Godfrey J, Benson JDM. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012;53(9):1666\u201376.","journal-title":"Leuk Lymphoma"},{"key":"2443_CR145","doi-asserted-by":"publisher","first-page":"1174138","DOI":"10.3389\/fimmu.2023.1174138","volume":"14","author":"P Farhangnia","year":"2023","unstructured":"Farhangnia P, Ghomi SM, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi A-A. Slam-family receptors come of age as a potential molecular target in cancer immunotherapy. Front Immunol. 2023;14:1174138.","journal-title":"Front Immunol"},{"issue":"1","key":"2443_CR146","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","volume":"34","author":"J Kikuchi","year":"2020","unstructured":"Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020;34(1):180\u201395.","journal-title":"Leukemia"},{"issue":"10","key":"2443_CR147","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.humimm.2009.07.004","volume":"70","author":"M Bernal","year":"2009","unstructured":"Bernal M, Garrido P, Jim\u00e9nez P, Carretero R, Almagro M, L\u00f3pez P, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol. 2009;70(10):854\u20137.","journal-title":"Hum Immunol"},{"issue":"11","key":"2443_CR148","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/blood.V90.11.4266","volume":"90","author":"TH Landowski","year":"1997","unstructured":"Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997;90(11):4266\u201370.","journal-title":"Blood"},{"issue":"10","key":"2443_CR149","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1111\/cas.15087","volume":"112","author":"S Ikeda","year":"2021","unstructured":"Ikeda S, Tagawa H. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma. Cancer Sci. 2021;112(10):3995\u20134004.","journal-title":"Cancer Sci"},{"issue":"5","key":"2443_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064835","volume":"8","author":"S Sarkar","year":"2013","unstructured":"Sarkar S, Germeraad WT, Rouschop KM, Steeghs EM, Gelder Mv, Bos GM, et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One. 2013;8(5):e64835.","journal-title":"PLoS One"},{"issue":"5","key":"2443_CR151","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"1_Supplement","key":"2443_CR152","doi-asserted-by":"publisher","first-page":"194.37","DOI":"10.4049\/jimmunol.202.Supp.194.37","volume":"202","author":"ER Cluff","year":"2019","unstructured":"Cluff ER, Nolan J, Collins C, Varadaraj A, Rajasekaran N. Hypoxia-inducible factor-1\u03b1 is upregulated in natural killer cells by interleukin-2 and hypoxia via PI3K\/mTOR signaling pathway. J Immunol. 2019;202(1_Supplement):194.37-37.","journal-title":"J Immunol"},{"key":"2443_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02277-x","volume":"12","author":"MG Lamb","year":"2021","unstructured":"Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021;12:1\u201319.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"2443_CR154","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12185-012-1069-y","volume":"95","author":"N Goda","year":"2012","unstructured":"Goda N, Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol. 2012;95(5):457\u201363.","journal-title":"Int J Hematol"},{"key":"2443_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1015402","volume":"12","author":"V Raimondi","year":"2022","unstructured":"Raimondi V, Toscani D, Marchica V, Burroughs-Garcia J, Storti P, Giuliani N. Metabolic features of myeloma cells in the context of bone microenvironment: implication for the pathophysiology and clinic of myeloma bone disease. Front Oncol. 2022;12:1015402.","journal-title":"Front Oncol"},{"key":"2443_CR156","doi-asserted-by":"publisher","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","volume":"73","author":"ZH Wang","year":"2021","unstructured":"Wang ZH, Peng WB, Zhang P, Yang XP, Zhou Q. Lactate in the tumour microenvironment: from immune modulation to therapy. EBioMedicine. 2021;73:103627.","journal-title":"EBioMedicine"},{"issue":"2","key":"2443_CR157","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4049\/jimmunol.1402643","volume":"195","author":"A Zingoni","year":"2015","unstructured":"Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, et al. Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells. J Immunol. 2015;195(2):736\u201348.","journal-title":"J Immunol"},{"issue":"4","key":"2443_CR158","first-page":"652","volume":"8","author":"J-H Gong","year":"1994","unstructured":"Gong J-H, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"2443_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki A-M, Liu H, \u00d6zkazanc D, Ku\u010derov\u00e1 L, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15(1):164.","journal-title":"J Hematol Oncol"},{"key":"2443_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"issue":"4","key":"2443_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol. 2021;10(4):e1274.","journal-title":"Clin Transl Immunol"},{"key":"2443_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy\u2013advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91.","journal-title":"Front Immunol"},{"issue":"3","key":"2443_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030706","volume":"12","author":"A Pfefferle","year":"2020","unstructured":"Pfefferle A, Huntington ND. You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers (Basel). 2020;12(3):706.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2443_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov. 2024;10(1):318.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2443_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06438-7","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang B, Yang M, Zhang W, Liu N, Wang D, Jing L, et al. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. Cell Death Dis. 2024;15(1):50.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2443_CR166","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","volume":"125","author":"NN Shah","year":"2015","unstructured":"Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, et al. Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell\u2013depleted stem cell transplantation. Blood. 2015;125(5):784\u201392.","journal-title":"Blood"},{"key":"2443_CR167","doi-asserted-by":"crossref","unstructured":"Salavati MS, Tavakoli S, Tavoosi S, Nodehi M, Baghsheikhi AH, Vaezi M, et al. CAR-NK Cells as Promising Immune Therapeutics: Platforms and Current Progress. International Journal of Cancer Management. 2024.;17(1):e145431.","DOI":"10.5812\/ijcm-145431"},{"key":"2443_CR168","doi-asserted-by":"publisher","first-page":"255264","DOI":"10.3389\/fimmu.2017.00329","volume":"8","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol. 2017;8:255264.","journal-title":"Front Immunol"},{"key":"2443_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584099","volume":"11","author":"X Zhao","year":"2020","unstructured":"Zhao X, Cai L, Hu Y, Wang H. Cord-blood natural killer cell-based immunotherapy for cancer. Front Immunol. 2020;11:584099.","journal-title":"Front Immunol"},{"key":"2443_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207276","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lam KP, Xu S. Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol. 2023;14:1207276.","journal-title":"Front Immunol"},{"issue":"4","key":"2443_CR171","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274\u201383.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2443_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03461-x","volume":"14","author":"W Wen","year":"2023","unstructured":"Wen W, Chen X, Shen XY, Li HY, Zhang F, Fang FQ, et al. Enhancing cord blood stem cell-derived NK cell growth and differentiation through hyperosmosis. Stem Cell Res Ther. 2023;14(1):295.","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"2443_CR173","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/sctm.20-0459","volume":"10","author":"J Arias","year":"2021","unstructured":"Arias J, Yu J, Varshney M, Inzunza J, Nalvarte I. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions. Stem Cells Transl Med. 2021;10(7):987\u201395.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2443_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00610-z","volume":"12","author":"M Bakhtiyaridovvombaygi","year":"2024","unstructured":"Bakhtiyaridovvombaygi M, Yazdanparast S, Kheyrandish S, Safdari SM, Amiri Samani F, Sohani M, et al. Harnessing natural killer cells for refractory\/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective. Biomark Res. 2024;12(1):66.","journal-title":"Biomark Res"},{"issue":"2","key":"2443_CR175","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181-92 e5.","journal-title":"Cell Stem Cell."},{"key":"2443_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","volume":"13","author":"BH Goldenson","year":"2022","unstructured":"Goldenson BH, Hor P, Kaufman DS. Ipsc-derived natural killer cell therapies-expansion and targeting. Front Immunol. 2022;13:841107.","journal-title":"Front Immunol"},{"issue":"1","key":"2443_CR177","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RG, Wang J, Bos GM, Germeraad WT. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.","journal-title":"J Hematol Oncol"},{"key":"2443_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115123","volume":"165","author":"X Lin","year":"2023","unstructured":"Lin X, Sun Y, Dong X, Liu Z, Sugimura R, Xie G. Ipsc-derived CAR-NK cells for cancer immunotherapy. Biomed Pharmacother. 2023;165:115123.","journal-title":"Biomed Pharmacother"},{"key":"2443_CR179","doi-asserted-by":"publisher","unstructured":"Temples MN, Sharma B. Manufacturing of natural killer cells for treating solid malignancies. Journal of Immunology and Regenerative Medicine. 2020;10:100031. https:\/\/doi.org\/10.1016\/j.regen.2020.100031.","DOI":"10.1016\/j.regen.2020.100031"},{"issue":"1\u20132","key":"2443_CR180","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1615\/CritRevOncog.2014010931","volume":"19","author":"N Lapteva","year":"2014","unstructured":"Lapteva N, Szmania SM, van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014;19(1\u20132):121\u201332.","journal-title":"Crit Rev Oncog"},{"issue":"4","key":"2443_CR181","doi-asserted-by":"publisher","first-page":"647","DOI":"10.20892\/j.issn.2095-3941.2019.0187","volume":"16","author":"F Fang","year":"2019","unstructured":"Fang F, Wang W, Chen M, Tian Z, Xiao W. Technical advances in NK cell-based cellular immunotherapy. Cancer Biol Med. 2019;16(4):647\u201354.","journal-title":"Cancer Biol Med"},{"key":"2443_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.802906","volume":"13","author":"M Gurney","year":"2022","unstructured":"Gurney M, Kundu S, Pandey S, O\u2019Dwyer M. Feeder cells at the interface of natural killer cell activation, expansion and gene editing. Front Immunol. 2022;13:802906.","journal-title":"Front Immunol"},{"issue":"5","key":"2443_CR183","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jcyt.2015.03.611","volume":"17","author":"M Granzin","year":"2015","unstructured":"Granzin M, Soltenborn S, Muller S, Kollet J, Berg M, Cerwenka A, et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy. 2015;17(5):621\u201332.","journal-title":"Cytotherapy"},{"issue":"3","key":"2443_CR184","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5045\/br.2014.49.3.154","volume":"49","author":"DS Bae","year":"2014","unstructured":"Bae DS, Lee JK. Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res. 2014;49(3):154\u201361.","journal-title":"Blood Res"},{"issue":"4","key":"2443_CR185","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00262-022-03299-x","volume":"72","author":"NA Beelen","year":"2023","unstructured":"Beelen NA, Ehlers FAI, Bos GMJ, Wieten L. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunol Immunother. 2023;72(4):797\u2013804.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2443_CR186","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7(1):e30264.","journal-title":"PLoS One"},{"issue":"1","key":"2443_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51287-6","volume":"9","author":"EO Ojo","year":"2019","unstructured":"Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, et al. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019;9(1):14916.","journal-title":"Sci Rep"},{"key":"2443_CR188","doi-asserted-by":"publisher","unstructured":"Oberoi P, Kamenjarin K, Ossa JFV, Uherek B, Bonig H, Wels WS. Directed differentiation of mobilized hematopoietic stem and progenitor cells into functional NK cells with enhanced antitumor activity. Cells. 2020;9(4):811. https:\/\/doi.org\/10.3390\/cells9040811.","DOI":"10.3390\/cells9040811"},{"key":"2443_CR189","doi-asserted-by":"publisher","first-page":"1533044","DOI":"10.3389\/fimmu.2025.1533044","volume":"16","author":"DH Jo","year":"2025","unstructured":"Jo DH, Kaczmarek S, Khan AUH, Pervin J, Clark DM, Gadde S, et al. Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression. Front Immunol. 2025;16:1533044.","journal-title":"Front Immunol"},{"issue":"3","key":"2443_CR190","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"issue":"8","key":"2443_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"A Leivas","year":"2021","unstructured":"Leivas A, Valeri A, Cordoba L, Garcia-Ortiz A, Ortiz A, Sanchez-Vega L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11(8):146.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2443_CR192","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00461-8","volume":"12","author":"Q Ren","year":"2023","unstructured":"Ren Q, Zu Y, Su H, Lu Q, Xiang B, Luo Y, et al. Single VHH-directed BCMA CAR-NK cells for multiple myeloma. Exp Hematol Oncol. 2023;12(1):98.","journal-title":"Exp Hematol Oncol"},{"key":"2443_CR193","doi-asserted-by":"publisher","unstructured":"Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, et al. CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo. Int J Mol Sci. 2023;24(17):13364. https:\/\/doi.org\/10.3390\/ijms241713364.","DOI":"10.3390\/ijms241713364"},{"issue":"4","key":"2443_CR194","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.bbmt.2014.12.037","volume":"21","author":"JL Oyer","year":"2015","unstructured":"Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solh MM, Zakari A, et al. Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach. Biol Blood Marrow Transplant. 2015;21(4):632\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2443_CR195","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","volume":"18","author":"JL Oyer","year":"2016","unstructured":"Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment. Cytotherapy. 2016;18(5):653\u201363.","journal-title":"Cytotherapy"},{"key":"2443_CR196","doi-asserted-by":"publisher","unstructured":"Maia A, Tarannum M, Lerias JR, Piccinelli S, Borrego LM, Maeurer M, et al. Building a better defense: expanding and improving natural killer cells for adoptive cell therapy. Cells. 2024;13(5):451. https:\/\/doi.org\/10.3390\/cells13050451.","DOI":"10.3390\/cells13050451"},{"issue":"10","key":"2443_CR197","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0198-8859(01)00313-5","volume":"62","author":"S Carlens","year":"2001","unstructured":"Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, et al. A new method for in vitro expansion of cytotoxic human CD3\u2212CD56+ natural killer cells. Hum Immunol. 2001;62(10):1092\u20138.","journal-title":"Hum Immunol"},{"key":"2443_CR198","doi-asserted-by":"crossref","unstructured":"Motais B, Charvatova S, Walek Z, Hrdinka M, Smolarczyk R, Cichon T, et al. Selection, expansion, and unique pretreatment of allogeneic human natural killer cells with anti-CD38 monoclonal antibody for efficient multiple myeloma treatment. Cells. 2021;10(5):967.","DOI":"10.3390\/cells10050967"},{"key":"2443_CR199","doi-asserted-by":"publisher","unstructured":"Motais B, Charvatova S, Walek Z, Hajek R, Bago JR. NK92 expressing anti-BCMA CAR and secreted TRAIL for the treatment of multiple myeloma: preliminary in vitro assessment. Cells. 2023;12(23):2748. https:\/\/doi.org\/10.3390\/cells12232748.","DOI":"10.3390\/cells12232748"},{"key":"2443_CR200","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5562630","volume":"2021","author":"S Luanpitpong","year":"2021","unstructured":"Luanpitpong S, Poohadsuan J, Klaihmon P, Issaragrisil S. Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies. J Immunol Res. 2021;2021:5562630.","journal-title":"J Immunol Res"},{"key":"2443_CR201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383136","volume":"15","author":"MW Moles","year":"2024","unstructured":"Moles MW, Erdlei H, Menzel L, Massaro M, Fiori A, Bunse M, et al. CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma. Front Immunol. 2024;15:1383136.","journal-title":"Front Immunol"},{"issue":"12","key":"2443_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123390","volume":"10","author":"A Bashiri Dezfouli","year":"2021","unstructured":"Bashiri Dezfouli A, Yazdi M, Pockley AG, Khosravi M, Kobold S, Wagner E, et al. NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development. Cells. 2021;10(12):3390.","journal-title":"Cells"},{"issue":"1","key":"2443_CR203","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/imr.13255","volume":"320","author":"Y Li","year":"2023","unstructured":"Li Y, Rezvani K, Rafei H. Next-generation chimeric antigen receptors for T-and natural killer-cell therapies against cancer. Immunol Rev. 2023;320(1):217\u201335.","journal-title":"Immunol Rev"},{"issue":"11","key":"2443_CR204","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJ, Sievers SA, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452\u201365.","journal-title":"Mol Ther"},{"key":"2443_CR205","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1182\/blood-2023-187954","volume":"142","author":"VM Giordani","year":"2023","unstructured":"Giordani VM, Mirazee J, Pouzolles M, Benzaoui M, Chien CD, Majdoul S, et al. Generation of hinge-modified human CD19 chimeric antigen receptor (CAR) T cells for the treatment of CD19-low leukemia. Blood. 2023;142:6819.","journal-title":"Blood"},{"key":"2443_CR206","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12920-019-0489-4","volume":"12","author":"SV Kulemzin","year":"2019","unstructured":"Kulemzin SV, Matvienko DA, Sabirov AH, Sokratyan AM, Chernikova DS, Belovezhets TN, et al. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines. BMC Med Genomics. 2019;12:87\u201395.","journal-title":"BMC Med Genomics"},{"issue":"2","key":"2443_CR207","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","volume":"19","author":"S Oelsner","year":"2017","unstructured":"Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19(2):235\u201349.","journal-title":"Cytotherapy"},{"issue":"7","key":"2443_CR208","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","volume":"194","author":"K T\u00f6pfer","year":"2015","unstructured":"T\u00f6pfer K, Cartellieri M, Michen S, Wiedemuth R, M\u00fcller N, Lindemann D, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201\u201312.","journal-title":"J Immunol"},{"key":"2443_CR209","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1016\/j.htct.2023.09.1007","volume":"45","author":"D Schmidt","year":"2023","unstructured":"Schmidt D, Ebrahimabadi S, Tirapelle M, Covas D, Pican\u00e7o-Castro V. CD19 CAR-NK construction with a new hinge and GITRL co-expression for Treg activity inhibition. Hematol Transfus Cell Ther. 2023;45:S548.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2443_CR210","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.","journal-title":"Front Immunol"},{"issue":"10","key":"2443_CR211","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"7_Supplement","key":"2443_CR212","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2911","volume":"83","author":"A Chen","year":"2023","unstructured":"Chen A. Abstract 2911: identification of novel CAR transmembrane and endodomains for improved persistence and cytotoxicity of NK cell therapies. Cancer Res. 2023;83(7_Supplement):2911.","journal-title":"Cancer Res"},{"key":"2443_CR213","doi-asserted-by":"crossref","unstructured":"Williams MD, Chen AT, Stone MR, Guo L, Belmont BJ, Turk R, et al. TRAFfic signals: High-throughput CAR discovery in NK cells reveals novel TRAF-binding endodomains that drive enhanced persistence and cytotoxicity. bioRxiv. 2023;2023.08.02.551530.","DOI":"10.1101\/2023.08.02.551530"},{"key":"2443_CR214","doi-asserted-by":"crossref","unstructured":"Wlodarczyk M, Pyrzynska B. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer. Cancers (Basel). 2022;15(1):117.","DOI":"10.3390\/cancers15010117"},{"issue":"10","key":"2443_CR215","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","volume":"28","author":"J Moscarelli","year":"2022","unstructured":"Moscarelli J, Zahavi D, Maynard R, Weiner LM. The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells. Transplant Cell Ther. 2022;28(10):650\u20136.","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2443_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27196","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian K, Zhang D, Hu P, He Z, et al. CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon. 2024;10(5):e27196.","journal-title":"Heliyon"},{"issue":"6","key":"2443_CR217","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia. 2010;24(6):1160\u201370.","journal-title":"Leukemia"},{"issue":"1","key":"2443_CR218","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06432-3","volume":"23","author":"H Lin","year":"2025","unstructured":"Lin H, Zhang L, Ge T, An N, Yang Y, Zhang Y, et al. Engineering CD5-targeting CAR-NK cells from peripheral blood for the treatment of CD5-positive hematological malignancies. J Transl Med. 2025;23(1):409.","journal-title":"J Transl Med"},{"key":"2443_CR219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611163","volume":"11","author":"P Schmidt","year":"2020","unstructured":"Schmidt P, Raftery MJ, Pecher G. Engineering NK cells for CAR therapy-recent advances in gene transfer methodology. Front Immunol. 2020;11:611163.","journal-title":"Front Immunol"},{"key":"2443_CR220","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","volume":"6","author":"M Carlsten","year":"2015","unstructured":"Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266.","journal-title":"Front Immunol"},{"key":"2443_CR221","doi-asserted-by":"publisher","unstructured":"Hambach J, Riecken K, Cichutek S, Schutze K, Albrecht B, Petry K, et al. Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs). Cells. 2020;9(2):321. https:\/\/doi.org\/10.3390\/cells9020321.","DOI":"10.3390\/cells9020321"},{"issue":"7","key":"2443_CR222","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jcyt.2023.03.006","volume":"25","author":"M Karvouni","year":"2023","unstructured":"Karvouni M, Vidal-Manrique M, Susek KH, Hussain A, Gilljam M, Zhang Y, et al. Challenges in alphaCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide. Cytotherapy. 2023;25(7):763\u201372.","journal-title":"Cytotherapy"},{"issue":"6","key":"2443_CR223","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-53 %@ 0028-4793.","journal-title":"N Engl J Med."},{"key":"2443_CR224","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/sj.gt.3301283","volume":"7","author":"K Frimpong","year":"2000","unstructured":"Frimpong K, Spector S. Cotransduction of nondividing cells using lentiviral vectors. Gene Ther. 2000;7:1562\u20139.","journal-title":"Gene Ther"},{"issue":"10","key":"2443_CR225","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.exphem.2006.06.001","volume":"34","author":"F Micucci","year":"2006","unstructured":"Micucci F, Zingoni A, Piccoli M, Frati L, Santoni A, Galandrini R. High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. Exp Hematol. 2006;34(10):1344-5% @ 0301-472X.","journal-title":"Exp Hematol."},{"issue":"5","key":"2443_CR226","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI61852","volume":"122","author":"A Moiani","year":"2012","unstructured":"Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest. 2012;122(5):1653\u201366.","journal-title":"J Clin Invest"},{"issue":"4","key":"2443_CR227","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917\u201327.","journal-title":"Leukemia"},{"issue":"6","key":"2443_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2022.100236","volume":"2","author":"M Naeimi Kararoudi","year":"2022","unstructured":"Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, et al. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Rep Methods. 2022;2(6):100236.","journal-title":"Cell Rep Methods"},{"issue":"1","key":"2443_CR229","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol Ther. 2020;28(1):52-63 %@ 1525-0016.","journal-title":"Mol Ther."},{"key":"2443_CR230","doi-asserted-by":"publisher","first-page":"957 %@ 1664-322","DOI":"10.3389\/fimmu.2019.00957","volume":"10","author":"T Ingegnere","year":"2019","unstructured":"Ingegnere T, Mariotti FR, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing. Front Immunol. 2019;10:957 %@ 1664-3224.","journal-title":"Front Immunol."},{"issue":"3","key":"2443_CR231","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/156652321403140819122538","volume":"14","author":"A Williams","year":"2014","unstructured":"Williams A, Improving J. DNA vaccine performance through vector design. Curr Gene Ther. 2014;14(3):170-89 %@ 1566-5232.","journal-title":"Curr Gene Ther."},{"issue":"9","key":"2443_CR232","doi-asserted-by":"publisher","first-page":"e1341031 %@ 216","DOI":"10.1080\/2162402X.2017.1341031","volume":"6","author":"Y Chu","year":"2017","unstructured":"Chu Y, Yahr A, Huang B, Ayello J, Barth MS, Cairo M. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology. 2017;6(9):e1341031 %@ 2162-402X.","journal-title":"Oncoimmunology."},{"issue":"1","key":"2443_CR233","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10439-023-03309-8","volume":"52","author":"W Peng","year":"2024","unstructured":"Peng W, Polajzer T, Yao C, Miklavcic D. Dynamics of cell death due to electroporation using different pulse parameters as revealed by different viability assays. Ann Biomed Eng. 2024;52(1):22\u201335.","journal-title":"Ann Biomed Eng"},{"issue":"1","key":"2443_CR234","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean EM, McCarthy HO. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J Nanobiotechnology. 2024;22(1):552.","journal-title":"J Nanobiotechnology"},{"key":"2443_CR235","first-page":"353","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics. 2021;15:353\u201361.","journal-title":"Biologics"},{"issue":"1","key":"2443_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8(1):36.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2443_CR237","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/ni0903-815","volume":"4","author":"E Joly","year":"2003","unstructured":"Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4(9):815-%@ 1529-2908.","journal-title":"Nat Immunol."},{"issue":"22","key":"2443_CR238","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.1182\/blood-2011-11-389924","volume":"119","author":"SS Somanchi","year":"2012","unstructured":"Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood. 2012;119(22):5164\u201372.","journal-title":"Blood"},{"key":"2443_CR239","doi-asserted-by":"crossref","unstructured":"Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederst\u00e4dt A, \u2026 Rezvani K. Trogocytosis-mediated tumor relapse after CAR-NK cell therapy prevented by inhibitory CARs. Nat Med. 2022;28:2013\u20134.","DOI":"10.1038\/s41591-022-02003-x"},{"issue":"1","key":"2443_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17128-1","volume":"11","author":"Q Chen","year":"2020","unstructured":"Chen Q, Luo W, Veach RA, Hickman AB, Wilson MH, Dyda F. Structural basis of seamless excision and specific targeting by piggyBac transposase. Nat Commun. 2020;11(1):3446.","journal-title":"Nat Commun"},{"key":"2443_CR241","doi-asserted-by":"crossref","unstructured":"Bexte T, Botezatu L, Miskey C, Gierschek F, Moter A, Wendel P, et al. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors. Molecular Therapy. %@ 1525\u20130016. 2024.","DOI":"10.1016\/j.ymthe.2024.05.022"},{"issue":"5","key":"2443_CR242","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/pnasnexus\/pgae184","volume":"3","author":"ER Verhaar","year":"2024","unstructured":"Verhaar ER, van Keizerswaard WJC, Knoflook A, Balligand T, Ploegh HL. Nanobody-based CAR NK cells for possible immunotherapy of MICA(+) tumors. PNAS Nexus. 2024;3(5):184.","journal-title":"PNAS Nexus"},{"key":"2443_CR243","doi-asserted-by":"publisher","unstructured":"Edri A, Ben-Haim N, Hailu A, Brycman N, Berhani-Zipori O, Rifman J, et al. Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells. Int J Mol Sci. 2023;24(24):17231. https:\/\/doi.org\/10.3390\/ijms242417231.","DOI":"10.3390\/ijms242417231"},{"key":"2443_CR244","doi-asserted-by":"publisher","unstructured":"Troy E, Caporale J, Sezgin Y, Pereira MSF, Behbehani G, Lyberger J, et al. CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies. Blood Neoplasia. 2024;1(4):100032. https:\/\/doi.org\/10.1016\/j.bneo.2024.100032.","DOI":"10.1016\/j.bneo.2024.100032"},{"key":"2443_CR245","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2022-170501","volume":"140","author":"J Reiser","year":"2022","unstructured":"Reiser J, SRC, Mathavan K, Sillitti D, Mottershead C, Mattson B, et al. FT555: of-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma. Blood. 2022;140:4560\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2443_CR246","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2023-181613","volume":"142","author":"J Fu","year":"2023","unstructured":"Fu J, Jiang L, Zhu Z, Yan Y, Wu G, Wei M, et al. Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells. Blood. 2023;142(Supplement 1):4802.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2443_CR247","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2024-210041","volume":"144","author":"J Yang","year":"2024","unstructured":"Yang J, Jiang L, Zhu Z, Yan Y, Fu J, Wei M. CIB315: an allogeneic, off-the-shelf anti-GPRC5D iPSC-derived CAR-NK product targeting multiple myeloma. Blood. 2024;144(Supplement 1):2055.","journal-title":"Blood"},{"key":"2443_CR248","doi-asserted-by":"crossref","unstructured":"Zhuoxiao Cao CY, Yifang Wang, Chao Wang, Qingyang Wang, Gang Ye, Tingting Liu, Qin Wang, Huanyu Wang, Yanxue Gong, Biye Wang, Fuwei Jiang. Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myelom. Blood. 2022;140:7378.","DOI":"10.1182\/blood-2022-159289"},{"issue":"Supplement 1","key":"2443_CR249","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1182\/blood-2024-207942","volume":"144","author":"E Castellano","year":"2024","unstructured":"Castellano E, Garc\u00eda-Ortiz A, Ugalde L, Maroto Martin E, Encinas Mayoral J, Oliva R, et al. CRISPR\/Cas9 multi-editing enhances CAR NK cells therapeutic potential against multiple myeloma. Blood. 2024;144(Supplement 1):3442.","journal-title":"Blood"},{"key":"2443_CR250","doi-asserted-by":"crossref","unstructured":"Wen Lei HL, Wenhai Deng, Wei Chen, Yun Liang, Wenxia Gao, Xianggui Yuan, Shanshan Guo, Ping Li, Jinyong Wang, Xiangmin Tong, Yi Eve Sun, Aibin Liang, Wenbin Qian. Safety and feasibility of 4\u20131BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nature Cancer. 2025.","DOI":"10.1038\/s43018-025-00940-3"},{"key":"2443_CR251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414264","volume":"15","author":"R Yang","year":"2024","unstructured":"Yang R, Yang Y, Liu R, Wang Y, Yang R, He A. Advances in CAR-NK cell therapy for hematological malignancies. Front Immunol. 2024;15:1414264.","journal-title":"Front Immunol"},{"key":"2443_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117024","volume":"177","author":"M Bahramloo","year":"2024","unstructured":"Bahramloo M, Shahabi SA, Kalarestaghi H, Rafat A, Mazloumi Z, Samimifar A, et al. CAR-NK cell therapy in AML: current treatment, challenges, and advantage. Biomed Pharmacother. 2024;177:117024.","journal-title":"Biomed Pharmacother"},{"key":"2443_CR253","doi-asserted-by":"publisher","first-page":"1410519","DOI":"10.3389\/fimmu.2024.1410519","volume":"15","author":"J Jing","year":"2024","unstructured":"Jing J, Ma Y, Xie Z, Wang B, Chen Y, Chi E, et al. Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope. Front Immunol. 2024;15:1410519.","journal-title":"Front Immunol"},{"key":"2443_CR254","doi-asserted-by":"crossref","unstructured":"Binod Dhakal JGB, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour. Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed\/Refractory Multiple Myeloma. Blood. 2022;140 4586\u20137.","DOI":"10.1182\/blood-2022-166994"},{"key":"2443_CR255","doi-asserted-by":"crossref","unstructured":"Jode P, Goodridge RB, Sajid Mahmood, John Reiser, Svetlana Gaidarova, Robert Blum, Frank Cichocki, Hui-yi Chu, Greg Bonello, Tom Lee, Brian Groff, Miguel Meza, Yu-Waye Chu, Bruce Walcheck, Karl-Johan Malmberg, Jeffrey S. Miller, Armin Rehm, Uta Hopken, Bahram Valamehr. FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. Blood. 2020;136:4\u20135.","DOI":"10.1182\/blood-2020-142750"},{"issue":"4","key":"2443_CR256","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/biof.107","volume":"36","author":"NW Zwirner","year":"2010","unstructured":"Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. BioFactors. 2010;36(4):274\u201388.","journal-title":"BioFactors"},{"issue":"5","key":"2443_CR257","first-page":"879","volume":"11","author":"SS Choi","year":"2004","unstructured":"Choi SS, Chhabra VS, Nguyen QH, Ank BJ, Stiehm ER, Roberts RL. Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture. Clin Diagn Lab Immunol. 2004;11(5):879\u201388.","journal-title":"Clin Diagn Lab Immunol"},{"key":"2443_CR258","doi-asserted-by":"publisher","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9(12):e003894. https:\/\/doi.org\/10.1136\/jitc-2021-003894.","DOI":"10.1136\/jitc-2021-003894"},{"issue":"6","key":"2443_CR259","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood.2019000621","volume":"135","author":"HBR Zhu","year":"2020","unstructured":"Zhu HBR, Bjordahl R, Gaidarova S, Rogers P, Lee TT, Abujarour R, et al. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 2020;135(6):399\u2013410.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2443_CR260","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1182\/blood-2024-210243","volume":"144","author":"AS Boje","year":"2024","unstructured":"Boje AS, Langner A, Gehlert CL, Reitinger C, Nimmerjahn F, Murga Penas EM, et al. A novel platform technology for the development of NK cell-based cellular immunotherapies. Blood. 2024;144(Supplement 1):914.","journal-title":"Blood"},{"key":"2443_CR261","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-0716-0146-4_12","volume":"2086","author":"J Ludwig","year":"2020","unstructured":"Ludwig J, Hirschel M. Methods and Process Optimization for Large-Scale CAR T Expansion Using the G-Rex Cell Culture Platform. Methods Mol Biol. 2020;2086:165\u201377.","journal-title":"Methods Mol Biol"},{"key":"2443_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803380","volume":"13","author":"CDL Johnson","year":"2022","unstructured":"Johnson CDL, Zale NE, Frary ED, Lomakin JA. Feeder-cell-free and serum-free expansion of natural killer cells using Cloudz microspheres, G-Rex6M, and human platelet lysate. Front Immunol. 2022;13:803380.","journal-title":"Front Immunol"},{"issue":"357","key":"2443_CR263","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.","journal-title":"Sci Transl Med"},{"key":"2443_CR264","doi-asserted-by":"publisher","unstructured":"Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022;132(11):e154334. https:\/\/doi.org\/10.1172\/JCI154334.","DOI":"10.1172\/JCI154334"},{"key":"2443_CR265","doi-asserted-by":"crossref","unstructured":"Eskandarian Z, Hauch R, Schuster S, Winterberg D, Grabellus H, Imelmann C, Heitmann AL, Goos M, Rudloff K, Strauss J, Wolters-Eisfeld G, Nollau P, Klausz K, Sch\u00fcller U, Peipp M, Spohn M, Horstmann MA. Memory-like natural killer cell and CD19-antibody based immunotherapy in combination with tyrosine-kinase inhibition has antitumor effects against Ph(-like) acute lymphoblastic leukemia. Cancer Immunol Res. 2025;13(6):881-896.","DOI":"10.1158\/2326-6066.CIR-24-0746"},{"issue":"6","key":"2443_CR266","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/eji.201445200","volume":"45","author":"CM Huber","year":"2015","unstructured":"Huber CM, Doisne JM, Colucci F. IL-12\/15\/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol. 2015;45(6):1727\u201335.","journal-title":"Eur J Immunol"},{"key":"2443_CR267","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115718","volume":"168","author":"M Bakhtiyaridovvombaygi","year":"2023","unstructured":"Bakhtiyaridovvombaygi M, Yazdanparast S, Mikanik F, Izadpanah A, Parkhideh S, Shahbaz Ghasabeh A, et al. Cytokine-induced memory-like NK cells: emerging strategy for AML immunotherapy. Biomed Pharmacother. 2023;168:115718.","journal-title":"Biomed Pharmacother"},{"issue":"25","key":"2443_CR268","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122379119","volume":"119","author":"H Dong","year":"2022","unstructured":"Dong H, Ham JD, Hu G, Xie G, Vergara J, Liang Y, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(25):e2122379119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2443_CR269","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/blood.2020006619","volume":"136","author":"MMN Gang","year":"2020","unstructured":"Gang MMN, Wong P, Neal CC, Marsala L, Foster M, Schappe T, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020;136(20):2308\u201318.","journal-title":"Blood"},{"key":"2443_CR270","doi-asserted-by":"publisher","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","volume":"14","author":"B He","year":"2023","unstructured":"He B, Mai Q, Pang Y, Deng S, He Y, Xue R, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442.","journal-title":"Front Immunol"},{"issue":"7","key":"2443_CR271","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"LDB Lee","year":"2018","unstructured":"Lee LDB, Chaplin N, Philip B, Chin M, Galas-Filipowicz D, Onuoha S, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood. 2018;131(7):746\u201358.","journal-title":"Blood"},{"issue":"2","key":"2443_CR272","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2017.302","volume":"32","author":"KH Chen","year":"2018","unstructured":"Chen KH, Wada M, Pinz KG, Liu H, Shuai X, Chen X, et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia. 2018;32(2):402\u201312.","journal-title":"Leukemia"},{"issue":"1","key":"2443_CR273","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03326-6","volume":"20","author":"G Roex","year":"2022","unstructured":"Roex G, Campillo-Davo D, Flumens D, Shaw PAG, Krekelbergh L, De Reu H, et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J Transl Med. 2022;20(1):124.","journal-title":"J Transl Med"},{"key":"2443_CR274","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","volume":"10","author":"ABL Colamartino","year":"2019","unstructured":"Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, et al. Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector. Front Immunol. 2019;10:2873.","journal-title":"Front Immunol"},{"issue":"3","key":"2443_CR275","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2021.11.013","volume":"30","author":"F Fei","year":"2022","unstructured":"Fei F, Rong L, Jiang N, Wayne AS, Xie J. Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Mol Ther. 2022;30(3):1215\u201326.","journal-title":"Mol Ther"},{"key":"2443_CR276","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-4077","volume":"83","author":"C Yang","year":"2023","unstructured":"Yang C, Wang Y, Liu T, Wang C, Wang H, Wang Q, et al. Abstract 4077, dual-targeted CAR-NK cell therapy: optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma. Cancer Res. 2023;83:4077.","journal-title":"Cancer Res"},{"key":"2443_CR277","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.molimm.2021.07.018","volume":"138","author":"X Wang","year":"2021","unstructured":"Wang X, Martin AD, Negri KR, McElvain ME, Oh J, Wu ML, et al. Extensive functional comparisons between chimeric antigen receptors and T cell receptors highlight fundamental similarities. Mol Immunol. 2021;138:137\u201349.","journal-title":"Mol Immunol"},{"key":"2443_CR278","doi-asserted-by":"publisher","first-page":"1110482","DOI":"10.3389\/fimmu.2023.1110482","volume":"14","author":"M Barden","year":"2023","unstructured":"Barden M, Holzinger A, Velas L, Mezosi-Csaplar M, Szoor A, Vereb G, et al. CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation. Front Immunol. 2023;14:1110482.","journal-title":"Front Immunol"},{"key":"2443_CR279","doi-asserted-by":"publisher","unstructured":"Simon B, Harrer DC, Schuler-Thurner B, Schuler G, Uslu U. Arming T cells with a gp100-specific TCR and a CSPG4-specific CAR using combined DNA- and RNA-based receptor transfer. Cancers (Basel). 2019;11(5):696. https:\/\/doi.org\/10.3390\/cancers11050696.","DOI":"10.3390\/cancers11050696"},{"issue":"1","key":"2443_CR280","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11126-y","volume":"7","author":"E Walseng","year":"2017","unstructured":"Walseng E, Koksal H, Sektioglu IM, Fane A, Skorstad G, Kvalheim G, et al. A TCR-based chimeric antigen receptor. Sci Rep. 2017;7(1):10713.","journal-title":"Sci Rep"},{"issue":"2","key":"2443_CR281","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2256904","volume":"19","author":"T Huan","year":"2023","unstructured":"Huan T, Guan B, Li H, Tu X, Zhang C, Tang B. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer. Hum Vaccin Immunother. 2023;19(2):2256904.","journal-title":"Hum Vaccin Immunother"},{"key":"2443_CR282","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.838406","volume":"13","author":"J Hambach","year":"2022","unstructured":"Hambach J, Fumey W, Stahler T, Gebhardt AJ, Adam G, Weisel K, et al. Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells. Front Immunol. 2022;13:838406.","journal-title":"Front Immunol"},{"key":"2443_CR283","doi-asserted-by":"publisher","DOI":"10.3390\/antib13040097","author":"M Zhang","year":"2024","unstructured":"Zhang M, Loh HP, Goh Fang S, Yang Y, Lam KP, Xu S. Development of BCMA-targeted bispecific natural killer cell engagers for multiple myeloma treatment. Antibodies (Basel). 2024. https:\/\/doi.org\/10.3390\/antib13040097.","journal-title":"Antibodies (Basel)"},{"issue":"6","key":"2443_CR284","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1111\/bjh.19784","volume":"205","author":"ABL Zabaleta","year":"2024","unstructured":"Zabaleta ABL, Kim PS, Bisht K, Wang H, Van de Velde H, Lasa M, et al. A CD38\/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and\/or refractory to anti-CD38 monoclonal antibodies. Br J Haematol. 2024;205(6):2262\u20137.","journal-title":"Br J Haematol"},{"key":"2443_CR285","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103261","volume":"160","author":"MLC Gauthier","year":"2021","unstructured":"Gauthier MLC, Bensoussan D, Boura C, Decot V. Natural killer cells and monoclonal antibodies: two partners for successful antibody dependent cytotoxicity against tumor cells. Crit Rev Oncol Hematol. 2021;160:103261.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"2443_CR286","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","volume":"118","author":"DM Benson Jr","year":"2011","unstructured":"Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387\u201391.","journal-title":"Blood"},{"issue":"25","key":"2443_CR287","doi-asserted-by":"publisher","first-page":"17675","DOI":"10.18632\/oncotarget.24832","volume":"9","author":"NKL Vey","year":"2018","unstructured":"Vey NKL, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget. 2018;9(25):17675\u201388.","journal-title":"Oncotarget"},{"issue":"1","key":"2443_CR288","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall T, Andre P, Horowitz A, Ruan DF, Borst L, Zerbib R, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7(1):263.","journal-title":"J Immunother Cancer"},{"key":"2443_CR289","doi-asserted-by":"publisher","first-page":"1081546","DOI":"10.3389\/fimmu.2022.1081546","volume":"13","author":"K Yang","year":"2022","unstructured":"Yang K, Zhao Y, Sun G, Zhang X, Cao J, Shao M, et al. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Front Immunol. 2022;13:1081546.","journal-title":"Front Immunol"},{"key":"2443_CR290","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00977","volume":"9","author":"A Le Roy","year":"2018","unstructured":"Le Roy A, Prebet T, Castellano R, Goubard A, Riccardi F, Fauriat C, et al. Immunomodulatory drugs exert anti-leukemia effects in acute myeloid leukemia by direct and immunostimulatory activities. Front Immunol. 2018;9:977.","journal-title":"Front Immunol"},{"issue":"27","key":"2443_CR291","doi-asserted-by":"publisher","first-page":"23609","DOI":"10.18632\/oncotarget.4603","volume":"6","author":"CAM Fionda","year":"2015","unstructured":"Fionda CAM, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, et al. The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget. 2015;6(27):23609\u201330.","journal-title":"Oncotarget"},{"key":"2443_CR292","doi-asserted-by":"publisher","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020;12(2):265. https:\/\/doi.org\/10.3390\/cancers12020265.","DOI":"10.3390\/cancers12020265"},{"issue":"1","key":"2443_CR293","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01604-y","volume":"17","author":"D Sedloev","year":"2024","unstructured":"Sedloev D, Chen Q, Unglaub JM, Schanda N, Hao Y, Besiridou E, et al. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia. J Hematol Oncol. 2024;17(1):85.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2443_CR294","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbrc.2011.10.057","volume":"415","author":"X Wu","year":"2011","unstructured":"Wu X, Shao Y, Tao Y, Ai G, Wei R, Meng X, et al. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I. Biochem Biophys Res Commun. 2011;415(1):187\u201392.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"2443_CR295","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03818-y","volume":"73","author":"CH Quinn","year":"2024","unstructured":"Quinn CH, Julson JR, Markert HR, Nazam N, Butey S, Stewart JE, et al. Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma. Cancer Immunol Immunother. 2024;73(11):221.","journal-title":"Cancer Immunol Immunother"},{"key":"2443_CR296","doi-asserted-by":"publisher","unstructured":"Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 2020;8(1):e000131. https:\/\/doi.org\/10.1136\/jitc-2019-000131.","DOI":"10.1136\/jitc-2019-000131"},{"key":"2443_CR297","doi-asserted-by":"crossref","unstructured":"Alici KHSSMAKWH-GLE. Combination of herpes-simplex based oncolytic viruses (HSV-OV) with natural killer (NK) cells in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2019;19(10):e169.","DOI":"10.1016\/j.clml.2019.09.282"},{"issue":"21","key":"2443_CR298","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood.V124.21.4778.4778","volume":"124","author":"C Parrish","year":"2014","unstructured":"Parrish C, Scott GB, Coffey M, Melcher A, Errington-Mais F, Cook G. Combination therapy with reovirus and immunomodulatory drugs induces direct oncolytic and immune-mediated killing of multiple myeloma cells and overcomes stromal-mediated microenvironmental protection. Blood. 2014;124(21):4778.","journal-title":"Blood"},{"key":"2443_CR299","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1535-7163.MCT-19-0489","volume":"16","author":"YY Ng","year":"2020","unstructured":"Ng YY, Tay JCK, Wang S. CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Mol Ther. 2020;16:75\u201385.","journal-title":"Mol Ther"},{"issue":"1","key":"2443_CR300","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0275-9","volume":"5","author":"V Kremer","year":"2017","unstructured":"Kremer V, Ligtenberg MA, Zendehdel R, Seitz C, Duivenvoorden A, Wennerberg E, et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer. 2017;5(1):73.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2443_CR301","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","volume":"24","author":"NT Schomer","year":"2022","unstructured":"Schomer NT, Jiang ZK, Lloyd MI, Klingemann H, Boissel L. Ccr7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. Cytotherapy. 2022;24(8):827\u201334.","journal-title":"Cytotherapy"},{"issue":"5","key":"2443_CR302","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/bjc.2016.20","volume":"114","author":"E Viziteu","year":"2016","unstructured":"Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, et al. Chetomin, targeting HIF-1alpha\/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer. 2016;114(5):519\u201323.","journal-title":"Br J Cancer"},{"key":"2443_CR303","doi-asserted-by":"publisher","unstructured":"Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel). 2021;13(9):2018. https:\/\/doi.org\/10.3390\/cancers13092018.","DOI":"10.3390\/cancers13092018"},{"issue":"4","key":"2443_CR304","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","volume":"26","author":"A Rea","year":"2025","unstructured":"Rea A, Santana-Hernandez S, Villanueva J, Sanvicente-Garcia M, Cabo M, Suarez-Olmos J, et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFbeta and activin A suppression. Nat Immunol. 2025;26(4):582\u201394.","journal-title":"Nat Immunol"},{"issue":"23","key":"2443_CR305","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood.2021015184","volume":"140","author":"F Cichocki","year":"2022","unstructured":"Cichocki F, Goodridge JP, Bjordahl R, Mahmood S, Davis ZB, Gaidarova S, et al. Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 2022;140(23):2451\u201362.","journal-title":"Blood"},{"issue":"1","key":"2443_CR306","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283.","journal-title":"Nat Commun"},{"issue":"6383","key":"2443_CR307","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.aao0505","volume":"359","author":"Andrade L de Ferrari","year":"2018","unstructured":"de Ferrari Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018;359(6383):1537\u201342.","journal-title":"Science"},{"issue":"4","key":"2443_CR308","doi-asserted-by":"publisher","first-page":"295","DOI":"10.18609\/cgti.2018.030","volume":"4","author":"KJ Imbach","year":"2018","unstructured":"Imbach KJ, Patel A, Levine AD. Ethical considerations in the translation of CAR-T cell therapies. Cell Gene Ther Insights. 2018;4(4):295\u2013307.","journal-title":"Cell Gene Ther Insights"},{"issue":"1","key":"2443_CR309","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2415187","volume":"20","author":"W Li","year":"2024","unstructured":"Li W, Feng J, Peng J, Zhang X, Aziz AUR, Wang D. Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: a bibliometric analysis from 2004 to 2023. Hum Vaccin Immunother. 2024;20(1):2415187.","journal-title":"Hum Vaccin Immunother"},{"key":"2443_CR310","doi-asserted-by":"publisher","unstructured":"Li W, Wang X, Zhang X, Aziz AUR, Wang D. CAR-NK cell therapy: a transformative approach to overcoming oncological challenges. Biomolecules. 2024;14(8):1035. https:\/\/doi.org\/10.3390\/biom14081035.","DOI":"10.3390\/biom14081035"},{"issue":"1","key":"2443_CR311","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1631\/jzus.B1800421","volume":"20","author":"SS Ren","year":"2019","unstructured":"Ren SS, Deng JW, Hong M, Ren YL, Fu HJ, Liu YN, et al. Ethical considerations of cellular immunotherapy for cancer. J Zhejiang Univ Sci B. 2019;20(1):23\u201331.","journal-title":"J Zhejiang Univ Sci B"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02443-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02443-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02443-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:04:42Z","timestamp":1762877082000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02443-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":311,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02443-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"485"}}